Table 6. Impact of praziquantel treatment on prevalence of infection in schools with high or moderate baseline prevalence of S. haematobium and S. mansoni.

	S. haematobium
	Annual treatment for all people age 5 years and older		Treatment every other year for school-age children only
	Baseline S. haematobium prevalence ≥50%	Baseline S. haematobium prevalence 10–49%	Baseline S. haematobium prevalence 10–49%
	N = 161 schools, 2415 children	N = 72 schools, 1080 children	N = 295 schools, 4425 children
Baseline– 2009
Mean prevalence	70.3%	26.5%	24.7%
Median prevalence	66.7%	23.3%	20.0%
Range	53.3–100%	13.3–46.7%	13.3–46.7%
Follow-up– 2015
Mean prevalence	11.3%	4.8%	4.19%
Median prevalence	6.7%	0.0%	0.0%
Range	0–100%	0–6.7%	0–87%
	S. mansonia
	Annual treatment for all people age 5 years and older		Treatment every other year for school-age children only
	Baseline S. mansoni prevalence ≥50%	Baseline S. mansoni prevalence 10–49%	Baseline S. mansoni prevalence 10–49%
	N = 22 schools, 330 children	N = 30 schools, 450 children	N = 42 schools, 630 children
Baseline– 2009
Mean prevalence	70.9%	23.8%	21.1%
Median prevalence	76.7%	20.0%	16.7%
Range	53.3–93.3%	13.3%-46.7%	13.3–46.7%
Follow-up– 2015
Mean prevalence	9.1%	2.0%	4.6%
Median prevalence	0%	0.0%	0.0%
Range	0–60%	0–20%	0–60%

^aFor schools with moderate baseline prevalence of S. mansoni, those receiving annual MDA for all people age 5 years and older had a significantly lower prevalence of S. mansoni in 2015 (Welch’s t-test, p<0.0001) than did those schools receiving MDA every other year (Welch’s t-test, p = 0.02).